Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5AP | P20292 | 1/20 | 0.36 |
| ▸ | FEN1 | P39748 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5159931 | 0.87 | RAB9A (0.37) | ALOX5APFEN1KMT2ASMN1; SMN2RAB9A | |
| SCHEMBL23142701 | 0.81 | RAB9A (0.39) | RAB9APOLB | |
| SCHEMBL24922942 | 0.80 | HSD17B10 (0.44) | ALOX5APFEN1KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL24922956 | 0.80 | HSD17B10 (0.44) | ALOX5APFEN1KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL5160897 | 0.80 | HCRTR2 (0.33) | KMT2ASMN1; SMN2POLBUSP2 | |
| SCHEMBL27010065 | 0.79 | RAB9A (0.38) | RAB9AHSD17B10LMNAPOLB | |
| SCHEMBL5409090 | 0.78 | EPHX1 (0.37) | KMT2AMEN1SMN1; SMN2RAB9AALDH1A1 | |
| SCHEMBL6241038 | 0.77 | ALOX5AP (0.43) | ALOX5APFEN1KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL5160976 | 0.77 | SMN1; SMN2 (0.37) | ALOX5APFEN1KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL18015118 | 0.76 | ALOX5AP (0.45) | ALOX5APFEN1KMT2AMEN1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070232601-A1 | Vla-4 Inhibitor | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-10-04 | — | — | US | disclosed |
| EP-1757602-A1 | VLA-4 INHIBITOR | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-02-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232601-A1 | Vla-4 Inhibitor | VCAM1, ITGB4, ITGA4 | ALOX5AP 1041/4885FEN1 4799/4885KMT2A 1139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.